罗氟司特需要注意的地方有哪些？

Roflumilast is currently approved for the treatment of patients with chronic obstructive pulmonary disease. The drug belongs to the second-generation PDE4 inhibitor class and has anti-diabetic, anti-alcohol addiction, anti-tumor, and anti-inflammatory effects. In recent years, it has been discovered that roflumilast, like other PDE4 inhibitor drugs, has a neuroprotective effect, especially on cognitive function. Therefore, the drug can also treat central nervous degenerative diseases such as Parkinson's disease and Alzheimer's disease. So, what should we pay attention to with roflumilast? Let’s take a look!

What should we pay attention to when taking roflumilast?

Acute bronchospasm: Do not use to relieve acute bronchospasm.

Psychiatric events including suicidal behavior: Advise patients, their caregivers, and families to be alert to the emergence or worsening of insomnia, anxiety, depression, suicidal thoughts, or other mood changes, and to contact their health care provider if such changes occur. Carefully weigh the risks and benefits of treatment with DALIRESP in patients with a history of depression and/or suicidal thoughts or behaviors.

Weight Loss: Monitor your weight regularly. If unexplained or clinically significant weight loss occurs, evaluate weight loss and consider discontinuing use.

The above are the things that need to be paid attention to when taking roflumilast, and patients are advised to avoid lightning. If you need to purchase the drug Roflumilast, please contact your medical companion to place an order!

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and to help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.